This HTML5 document contains 144 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n8http://dx.doi.org/10.1200/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37103086
rdf:type
wikibase:Item
schema:description
vědecký článek 2008 nî lūn-bûn wetenschappelijk artikel 2008年学术文章 vitenskapelig artikkel 2008年学术文章 2008년 논문 scientific article published on December 2008 ২০০৮-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ 2008年学术文章 articol științific 2008年學術文章 tudományos cikk artigo científico (publicado na 2008) научная статья vedecký článok artikulong pang-agham 2008年の論文 vitskapeleg artikkel artículo científico publicado en 2008 мақолаи илмӣ บทความทางวิทยาศาสตร์ مقالة علمية نشرت في ديسمبر 2008 научни чланак 2008年学术文章 2008年學術文章 2008年學術文章 naučni članak სამეცნიერო სტატია article científic наукова стаття, опублікована в грудні 2008 2008年學術文章 videnskabelig artikel (udgivet 2008) научни чланак επιστημονικό άρθρο artículu científicu espublizáu en 2008 tieteellinen artikkeli мақолаи илмӣ wissenschaftlicher Artikel vetenskaplig artikel teaduslik artikkel artigo científico bài báo khoa học 2008年学术文章 article scientific bilimsel makale articolo scientifico 2008年學術文章 artigo científico (publicado na 2008) 2008年學術文章 artykuł naukowy opublikowany w grudniu 2008 научна статия scienca artikolo مقالهٔ علمی artikull shkencor article scientifique publié en 2008 mokslinis straipsnis գիտական հոդված מאמר מדעי سائنسی مضمون
p:P577
wds:Q37103086-BF1C232B-4AD5-4C4A-91AF-A5983485949D
wdt:P577
2008-12-01T00:00:00Z
p:P407
wds:Q37103086-BC7434FC-2D5A-4F4B-8B4A-A279370F34E4
wdt:P407
wd:Q1860
p:P2860
wds:Q37103086-0D5674DA-B3E5-4A56-81D9-06BABDB66159 wds:Q37103086-17489665-1361-4367-9AC7-27942A8F48C8 wds:Q37103086-39B0EEFD-46C2-4087-B2B9-8E04E101D86A wds:Q37103086-3F67D197-2447-427B-95D1-D9B304D8476D wds:Q37103086-1BC6C068-A548-4567-81DB-1B0C4BE2EB90 wds:Q37103086-25EC510C-D952-44D6-9EC0-B13864DBC188 wds:Q37103086-30E135D6-553A-4818-AF46-7D90379CE1FB wds:Q37103086-C34CA5F2-AEEE-438B-808E-E7B65E4D8713 wds:Q37103086-88D6C8D4-BB99-4221-B647-6CC206BDCC42 wds:Q37103086-9F327E94-FA8F-42B7-A595-02566EF95B1E wds:Q37103086-E256B83F-B827-49E4-B7BE-1E3E475F72E0 wds:Q37103086-EB0920F4-3BF0-4E6F-960F-F3F48579542C
wdt:P2860
wd:Q40182316 wd:Q72099581 wd:Q33730942 wd:Q52581305 wd:Q33942787 wd:Q36607545 wd:Q40441994 wd:Q28282767 wd:Q36537333 wd:Q33246752 wd:Q28183621 wd:Q36610990
p:P2093
wds:Q37103086-718388AE-7696-4A64-83C8-FEE9CB3CA810 wds:Q37103086-9D62290D-4004-4886-8264-6335482073A0 wds:Q37103086-BA4477C2-3B33-4220-B681-227570179FBE wds:Q37103086-D91B2081-AD81-41B7-A7C2-A05030842407 wds:Q37103086-CE1F645F-56A3-48AA-8EDC-13829673779C wds:Q37103086-EB99430B-5537-418F-8985-19FE81C1BAB6 wds:Q37103086-68847A96-ABE3-415E-BC70-CF507FC617C7
wdt:P2093
Alvaro Moreno-Aspitia David W Hillman Patrick J Flynn Tom R Fitch Martin Wiesenfeld Kendrith M Rowland Roscoe F Morton
rdfs:label
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
skos:prefLabel
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
schema:name
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
p:P50
wds:Q37103086-CFB38AB1-1452-49E1-86FE-76DC6026CEBB wds:Q37103086-45408041-B201-4CF5-BF57-DC4A3545F19F
wdt:P50
wd:Q18389345 wd:Q112850014
p:P1476
wds:Q37103086-72F0980E-7671-4328-8631-7FD6CD273B1A
wdt:P1476
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
p:P304
wds:Q37103086-0554D54A-DA13-49E4-9D16-1BBDD6F4E71A
wdt:P304
11-15
p:P31
wds:Q37103086-431FE7A6-B484-4E46-A89B-C60DA31638AD
wdt:P31
wd:Q13442814
p:P921
wds:Q37103086-95536812-06F0-48A9-B31E-5887B6AFE76E wds:Q37103086-345774C6-ECDB-4679-A973-C34AA4A067F4 wds:Q37103086-F6C7C7EE-BD12-454B-B2E7-F73CCCC3795E
wdt:P921
wd:Q42824440 wd:Q181600 wd:Q12859063
p:P698
wds:Q37103086-5AFA9F3C-A101-4661-B9FC-F105456CADEF
wdtn:P698
n11:19047293
wdt:P698
19047293
p:P1433
wds:Q37103086-4116C223-0044-4969-9589-581826BE9B0E
wdt:P1433
wd:Q400292
p:P433
wds:Q37103086-DB6A518D-1748-4301-8852-64E6B97E558C
p:P478
wds:Q37103086-4F286A07-401C-4493-A213-83810DC74812
wdt:P433
1
wdt:P478
27
p:P356
wds:Q37103086-7D69E8A9-C873-4AD2-ABC4-0880044F757C
wdtn:P356
n8:JCO.2007.15.5242
wdt:P356
10.1200/JCO.2007.15.5242
p:P5875
wds:Q37103086-467FA10F-3B16-4DD6-B91D-0E5E00DFFCE8
wdt:P5875
23560226
p:P932
wds:Q37103086-F250CDCB-A4B8-4D4B-8A79-1F15CBF0C929
wdt:P932
2645094